Preeklampside stathmin-1: klinik şiddetin potansiyel göstergesi

Year 2025, Volume: 6 Issue: 5, 491 - 495, 24.10.2025

Zeynep Kayaoğlu Yıldırım , Gökhan Bolluk , Oğuzhan Zengi

Abstract

Amaç
Preeklampsi (PE), anormal plasentasyon ile ilişkili ve belirgin maternal-fetal morbiditeye yol açan multisistemik bir gebelik komplikasyonudur. Plasental disfonksiyonu ve hastalık şiddetini yansıtabilecek güvenilir biyobelirteçlerin tanımlanması klinik açıdan önemlidir. Bu çalışma, hücre proliferasyonu ve trofoblast invazyonunun düzenleyicisi olan Stathmin-1 (STMN-1) düzeylerinin, ciddi özellikleri olan ve olmayan PE olguları ile sağlıklı gebeler arasında karşılaştırılmasını amaçlamıştır.

Yöntemler
Bu prospektif, kesitsel çalışmaya 81 gebe kadın dahil edilmiştir: 41’i PE tanılı (22’si ciddi özellik göstermeyen, 19’u ciddi özellik gösteren) ve 40’ı normotansif sağlıklı kontrol grubundandır. Maternal serum STMN-1 düzeyleri, doğrulanmış bir ELISA yöntemi kullanılarak ölçülmüştür. Klinik özellikler, perinatal sonuçlar ve laboratuvar bulguları gruplar arasında karşılaştırılmıştır.

Bulgular
STMN-1 düzeyleri, PE grubunda (5,99 ± 3,37) kontrol grubuna (8,23 ± 3,42) kıyasla anlamlı olarak daha düşüktü (p = 0,004). Ciddi özellik göstermeyen PE olgularında kontrol grubuna kıyasla STMN-1 düzeyleri daha düşük olma eğiliminde olsa da bu fark istatistiksel olarak anlamlı değildi (p = 0,172). Ciddi özellik gösteren PE olgularında (4,88 ± 2,96), ciddi özellik göstermeyen PE grubuna (6,97 ± 3,46; p = 0,047) ve kontrol grubuna (p = 0,001) kıyasla STMN-1 düzeyleri anlamlı derecede düşüktü.

Sonuç
Maternal serum Stathmin-1 düzeyleri, özellikle ciddi preeklampsi olgularında belirgin şekilde azalmaktadır. Bu bulgular, STMN-1’in PE’nin tanısında ve şiddetinin değerlendirilmesinde potansiyel bir biyobelirteç olarak kullanılabileceğini düşündürmektedir. Bulguların tanısal ve prognostik değerini doğrulamak için daha geniş ölçekli çalışmalara ihtiyaç vardır.

Keywords

Stathmin-1 , preeklampsi , STMN-1 , trofoblast invazyonu

Stathmin-1 as a biomarker in preeclampsia: correlation with clinical severity

Abstract

Aims: Preeclampsia (PE) is a multisystem pregnancy disorder linked to abnormal placentation and significant maternal-fetal morbidity. Identifying reliable biomarkers that reflect placental dysfunction and disease severity remains clinically important. This study aimed to assess maternal serum levels of stathmin-1 (STMN-1), a regulator of cell proliferation and trophoblast invasion, in pregnancies complicated by PE with and without severe features, compared to healthy controls.
Methods: This prospective, cross-sectional study included 81 pregnant women: 41 with PE (22 without severe features and 19 with severe features) and 40 normotensive healthy controls. Maternal serum STMN-1 levels were measured using a validated ELISA method. Clinical characteristics, perinatal outcomes, and laboratory findings were compared across groups.
Results: STMN-1 levels were significantly lower in the PE group (5.99±3.37) than in controls (8.23±3.42)(p=0.004). Although not statistically significant (p=0.172), levels tended to be lower in PE without severe features compared to controls. STMN-1 levels were significantly lower in PE with severe features (4.88±2.96) than in PE without severe features (6.97±3.46, p=0.047) and controls (p=0.001).
Conclusion: Maternal serum STMN-1 levels decrease in PE, particularly in severe cases. These findings suggest that STMN1 may serve as a useful biomarker for identifying and assessing the severity of PE. Further large-scale studies are needed to confirm its diagnostic and prognostic value.

Keywords

Stathmin-1 , preeclampsia , STMN-1 , trophoblast invasion

References

• Karrar SA, Martingano DJ, Hong PL. Preeclampsia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2024.
• Torres-Torres J, Espino-Y-Sosa S, Martinez-Portilla R, et al. A narrative review on the pathophysiology of preeclampsia. Int J Mol Sci. 2024; 25(14):7569. doi:10.3390/ijms25147569
• Kim YJ. Pathogenesis and promising non-invasive markers for preeclampsia. Obstet Gynecol Sci. 2013;56(1):2-7. doi:10.5468/OGS.2013. 56.1.2
• Krzyszkowska M, Staniczek J, Kondracka A, et al. From biomarkers to the molecular mechanism of preeclampsia-a comprehensive literature review. Int J Mol Sci. 2023;24(17):13252. doi:10.3390/ijms241713252
• Gruslin A, Lemyre B. Pre-eclampsia: fetal assessment and neonatal outcomes. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):491-507. doi: 10.1016/j.bpobgyn.2011.02.004
• Clement MJ, Jourdain I, Lachkar S, et al. N-terminal stathmin-like peptides bind tubulin and impede microtubule assembly. Biochemistry. 2005;44:14616-14625. doi:10.1021/bi0512492
• Chen J, Abi-Daoud M, Wang A, et al. Stathmin 1 is a potential novel oncogene in melanoma. Oncogene. 2013;32(10):1330-1337. doi:10.1038/onc.2012.141
• Yoshie M, Tamura K, Kogo H. Differential localization of decidual stathmin during pregnancy in rats. Placenta. 2004;25(5):449-455. doi: 10.1016/j.placenta.2003.10.007
• Tian FJ, Qin CM, Li XC, et al. Decreased stathmin-1 expression inhibits trophoblast proliferation and invasion and is associated with recurrent miscarriage. Am J Pathol. 2015;185(10):2709-2721. doi:10.1016/j.ajpath. 2015.06.010
• Tamura K, Yoshie M, Nishi H, et al. Expression of stathmin in human uterus and decidualizing endometrial stromal cells. Reproduction. 2006; 132(4):625-636. doi:10.1530/rep.1.01148
• Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237-e260. doi:10.1097/AOG. 0000000000003891
• Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018;13:291-310. doi:10.1016/j.preghy.2018.05.004
• Semerci SY, Yücel B, Erbaş İM, Günkaya OS, Çetinkaya M. The possible association between neonatal morbidities and amniotic fluid pH and electrolyte levels in infants of preeclamptic mothers. Turk J Pediatr. 2021;63(5):867-874. doi:10.24953/turkjped.2021.05.014
• Fillion A, Guerby P, Menzies D, et al. Pathological investigation of placentas in preeclampsia (the PEARL study). Hypertens Pregnancy. 2021;40(1):56-62. doi:10.1080/10641955.2020.1866008
• Ali A, Addley S, Ong S. Three-dimensional indices of renal perfusion in normal pregnancy and pre-eclampsia. Ir J Med Sci. 2019;188(1):173-177. doi:10.1007/s11845-018-1844-8
• Tjoa ML, Oudejans CB, van Vugt JM, Blankenstein MA, van Wijk IJ. Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction. Hypertens Pregnancy. 2004;23(2):171-189. doi:10.1081/PRG-120028292
• Larsson N, Marklund U, Gradin HM, Brattsand G, Gullberg M. Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol Cell Biol. 1997;17(9):5530-5539. doi:10.1128/MCB.17.9.5530
• Bièche I, Maucuer A, Laurendeau I, et al. Expression of stathmin family genes in human tissues: non-neural-restricted expression for SCLIP.Genomics. 2003;81(4):400-410. doi:10.1016/s0888-7543(03) 00031-4
• Nie L, Zhang C, Song H, et al. Overexpression of stathmin 1 predicts poor prognosis and promotes cancer cell proliferation and migration in ovarian cancer. Dis Markers. 2022;2022:3554100. doi:10.1155/2022/ 3554100
• Watanabe A, Suzuki H, Yokobori T, et al. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma. Cancer Sci. 2014;105(6):690-696. doi: 10.1111/cas.12417
• Zhang X, Ji J, Yang Y, Zhang J, Shen L. Stathmin1 increases radioresistance by enhancing autophagy in non-small-cell lung cancer cells. Onco Targets Ther. 2016;9:2565-2574. doi:10.2147/OTT.S100468
• Yoshie M, Kashima H, Bessho T, Takeichi M, Isaka K, Tamura K. Expression of stathmin, a microtubule regulatory protein, is associated with the migration and differentiation of cultured early trophoblasts. Hum Reprod. 2008;23(12):2766-2774. doi:10.1093/humrep/den317
• Lin Y, Li C, Shan B, et al. Reduced stathmin-1 expression in natural killer cells associated with spontaneous abortion. Am J Pathol. 2011;178(2): 506-514. doi:10.1016/j.ajpath.2010.10.005
• Dayanan R, Bulan DD, Yucel KY. Diagnostic and prognostic role of thrombospondin-4 levels in pre-eclampsia: association with onset type, severity, and perinatal outcome. Int J Gynaecol Obstet. 2025;171(1):345-352. doi:10.1002/ijgo.70456